NI201500118A - Imidazopiridazinas sustituidas - Google Patents

Imidazopiridazinas sustituidas

Info

Publication number
NI201500118A
NI201500118A NI201500118A NI201500118A NI201500118A NI 201500118 A NI201500118 A NI 201500118A NI 201500118 A NI201500118 A NI 201500118A NI 201500118 A NI201500118 A NI 201500118A NI 201500118 A NI201500118 A NI 201500118A
Authority
NI
Nicaragua
Prior art keywords
compounds
imidazopyridazines
substitute
preparing
angiogenesis
Prior art date
Application number
NI201500118A
Other languages
English (en)
Inventor
Koppitz Marcus
Klar Ulrich
Margret Wengner Antje
Neuhaus Roland
Siemeister Gerhard
Brüning Michael
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50179606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500118(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NI201500118A publication Critical patent/NI201500118A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Compuestos de imidazopiridazina sustituida, métodos para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos, uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o angiogenésis, como un único agente o en combinación con otros ingredientes activos.
NI201500118A 2013-03-01 2015-09-01 Imidazopiridazinas sustituidas NI201500118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13157453 2013-03-01
EP13198930 2013-12-20

Publications (1)

Publication Number Publication Date
NI201500118A true NI201500118A (es) 2015-10-19

Family

ID=50179606

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500118A NI201500118A (es) 2013-03-01 2015-09-01 Imidazopiridazinas sustituidas

Country Status (36)

Country Link
US (1) US9512130B2 (es)
EP (1) EP2961752B1 (es)
JP (1) JP2016511252A (es)
KR (1) KR20150125654A (es)
CN (1) CN105008364B (es)
AP (1) AP2015008636A0 (es)
AU (1) AU2014222806A1 (es)
BR (1) BR112015020990A2 (es)
CA (1) CA2902978A1 (es)
CL (1) CL2015002433A1 (es)
CR (1) CR20150455A (es)
CU (1) CU20150094A7 (es)
CY (1) CY1119667T1 (es)
DK (1) DK2961752T3 (es)
EA (1) EA029027B1 (es)
ES (1) ES2651765T3 (es)
GT (1) GT201500247A (es)
HK (1) HK1213876A1 (es)
HR (1) HRP20171890T1 (es)
HU (1) HUE037417T2 (es)
IL (1) IL240348A0 (es)
LT (1) LT2961752T (es)
MX (1) MX2015011316A (es)
NI (1) NI201500118A (es)
NO (1) NO2961752T3 (es)
PE (1) PE20151759A1 (es)
PH (1) PH12015501913A1 (es)
PL (1) PL2961752T3 (es)
PT (1) PT2961752T (es)
RS (1) RS56665B1 (es)
SG (1) SG11201505882QA (es)
SI (1) SI2961752T1 (es)
TN (1) TN2015000371A1 (es)
TW (1) TW201437211A (es)
UY (1) UY35360A (es)
WO (1) WO2014131739A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914995A1 (en) * 2013-06-13 2014-12-18 Bayer Pharma Aktiengesellschaft Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer
TW201613927A (en) * 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
WO2016096610A1 (de) 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
EP3313521A1 (de) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
WO2018114578A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
WO2019002542A1 (en) * 2017-06-30 2019-01-03 Les Laboratoires Servier COMBINATION OF AN INHIBITOR OF MPS1 AND A TAXANE COMPOUND, USES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3104759A1 (de) * 1981-02-11 1982-08-19 Bayer Ag, 5090 Leverkusen Dihalogenierte imidazolcarbonsaeure-amide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JP2830210B2 (ja) * 1989-11-17 1998-12-02 日本曹達株式会社 α，β―不飽和ケトン類の合成法
US6068834A (en) * 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
FR2804955B1 (fr) * 2000-02-11 2003-02-14 Rhodia Chimie Sa Procede de fonctionnalisation d'une double liaison
CN101541801A (zh) * 2006-08-04 2009-09-23 武田药品工业株式会社 稠杂环衍生物及其用途
EP2240488B1 (en) * 2008-02-06 2016-11-02 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2547685A1 (en) * 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US9145419B2 (en) * 2010-04-28 2015-09-29 Bristol-Myers Squibb Company Imidazopyridazinyl compounds
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
JP6054869B2 (ja) * 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
WO2014020041A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer

Also Published As

Publication number Publication date
EA201591618A1 (ru) 2016-02-29
ES2651765T3 (es) 2018-01-29
KR20150125654A (ko) 2015-11-09
RS56665B1 (sr) 2018-03-30
WO2014131739A2 (en) 2014-09-04
PT2961752T (pt) 2017-12-18
EP2961752B1 (en) 2017-09-13
CA2902978A1 (en) 2014-09-04
TW201437211A (zh) 2014-10-01
WO2014131739A3 (en) 2014-12-04
US20160016959A1 (en) 2016-01-21
AU2014222806A1 (en) 2015-09-03
CR20150455A (es) 2015-10-26
PL2961752T3 (pl) 2018-02-28
PH12015501913A1 (en) 2016-01-04
SG11201505882QA (en) 2015-09-29
BR112015020990A2 (pt) 2017-07-18
IL240348A0 (en) 2015-09-24
UY35360A (es) 2014-09-30
CY1119667T1 (el) 2018-04-04
GT201500247A (es) 2017-10-05
SI2961752T1 (en) 2018-01-31
CN105008364B (zh) 2017-11-07
AP2015008636A0 (en) 2015-08-31
CN105008364A (zh) 2015-10-28
HUE037417T2 (hu) 2018-08-28
PE20151759A1 (es) 2015-12-20
MX2015011316A (es) 2015-12-03
EA029027B1 (ru) 2018-01-31
CL2015002433A1 (es) 2016-01-04
LT2961752T (lt) 2017-12-27
US9512130B2 (en) 2016-12-06
HRP20171890T1 (hr) 2018-01-12
JP2016511252A (ja) 2016-04-14
CU20150094A7 (es) 2016-05-30
EP2961752A2 (en) 2016-01-06
NO2961752T3 (es) 2018-02-10
HK1213876A1 (zh) 2016-07-15
DK2961752T3 (en) 2017-12-11
TN2015000371A1 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
NI201500118A (es) Imidazopiridazinas sustituidas
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
UY33598A (es) Imidazopiridazinas sustituidas
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20160433A (es) Nuevos compuestos
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY36983A (es) Pirazolopiridinaminas sustituidas
AR094934A1 (es) Imidazopiridazinas sustituidas
UY34630A (es) Imidazopiridazinas sustituidas con amino